Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.064 AUD | +6.67% | +4.92% | +45.45% |
Apr. 03 | Acrux, TruPharma Launch Dapsone 5% Gel in US | MT |
Feb. 29 | Transcript : Acrux Limited, H1 2024 Earnings Call, Feb 29, 2024 |
Sales 2024 * | 6.5M 4.21M | Sales 2025 * | 12.3M 7.97M | Capitalization | 18.61M 12.06M |
---|---|---|---|---|---|
Net income 2024 * | -3M -1.94M | Net income 2025 * | 2M 1.3M | EV / Sales 2024 * | 2.45 x |
Net cash position 2024 * | 2.7M 1.75M | Net cash position 2025 * | 5.2M 3.37M | EV / Sales 2025 * | 1.09 x |
P/E ratio 2024 * |
-4.92
x | P/E ratio 2025 * |
8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.31% |
Latest transcript on Acrux Limited
1 day | +6.67% | ||
1 week | +4.92% | ||
Current month | +33.33% | ||
1 month | +30.61% | ||
3 months | -11.11% | ||
6 months | +52.38% | ||
Current year | +45.45% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Kotsanis
CEO | Chief Executive Officer | - | 14-11-02 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21-06-20 |
Chief Tech/Sci/R&D Officer | - | 15-02-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Geoff Brooke
BRD | Director/Board Member | 68 | 16-05-31 |
Ross Dobinson
FOU | Founder | 72 | 97-12-31 |
Michael Kotsanis
CEO | Chief Executive Officer | - | 14-11-02 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 0.064 | +6.67% | 98 691 |
24-04-22 | 0.06 | 0.00% | 135,535 |
24-04-19 | 0.06 | +3.45% | 165,762 |
24-04-18 | 0.058 | -6.45% | 555,825 |
24-04-17 | 0.062 | +5.08% | 208,491 |
Delayed Quote Australian S.E., April 23, 2024 at 02:10 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+45.45% | 11.23M | |
+17.88% | 44.31B | |
+19.87% | 22.17B | |
+12.82% | 14.62B | |
+8.06% | 13.12B | |
+39.21% | 11.58B | |
-8.96% | 6.96B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+6.50% | 5.03B |
- Stock Market
- Equities
- ACR Stock